A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/3/2016
Start Date:December 2007
End Date:November 2012

Use our guide to learn which trials are right for you!

A Multi-center, Open-label, Phase I Study of Single Agent R7112 Administered Orally in Patients With Advanced Malignancies, Except All Forms of Leukaemia

This study will determine the maximum tolerated dose and the optimal associated 4 weekly
dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid
tumors. A first cohort of patients will receive the starting dose of 20mg/m2/day, once daily
for 10 days in each 28 day cycle. Subsequent cohorts of patients will receive dose
escalations, and possible changes in dosing schedule, based on tolerability and
pharmacokinetic knowledge gained from prior treatment cohorts. The anticipated time on study
treatment is until disease progression or intolerable toxicity.


Inclusion Criteria:

- adult patients, >=18 years of age;

- solid tumor malignancies;

- failed prior therapies, or no standard therapy available;

- ECOG performance status of 0-2.

Exclusion Criteria:

- patients receiving any other agent or therapy to treat their malignancy;

- pre-existing gastrointestinal disorders which may interfere with absorption of drugs;

- clinically significant cardiovascular disease.
We found this trial at
6
sites
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Bordeaux,
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials